# Genetics of transient amnesia highlights a vascular role in memory

Manuel A. Rivas<sup>1</sup>, FinnGen, Mark J. Daly<sup>2,3,4</sup>

E-mail: mrivas@stanford.edu and mjdaly@broadinstitute.org

- 1 Department of Biomedical Data Science, Stanford University, CA, USA
- 2 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
- 3 Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
- 4 Broad Institute of MIT and Harvard, Cambridge, MA, USA

## **Abstract**

Where memory is stored and how it is processed is poorly understood. Traditionally, genetics of low prevalence traits have been used to get a better understanding of naturally occuring conditions across species. Here, we conduct a genome-wide association of transient global amnesia (TGA), a specific type of heritable amnesia characterized by a sudden, temporary episode of memory loss, across 4,303 patients and over 1 million controls from three population biobanks in Finland, United States, and the United Kingdom, to better understand the genetic basis of memory. We find nine loci associated with TGA (p < 5x10-8) including a missense variant in *CRIP1* with high posterior probability (> .9) of being the causally relevant variant using fine-mapping, replicated across 3 cohorts. Furthermore, we find enrichment for a specific cell type, pericyte cells, which are a key part of the neurovascular unit, which includes astrocytes and neurons, and control interactions between neurons and the cerebral vasculature, implicating a direct vascular role in memory formation and retrieval. We anticipate these genetic studies at a larger scale to bring new biological understanding and therapeutic insights into the brain and memory.

### Introduction

Amnesia is a condition that affects memory, involving a loss of memory that may be partial or complete, temporary or permanent. It's directly related to memory because it specifically impacts the ability to recall information that was previously known or the ability to form new memories. Amnesia primarily impacts explicit (declarative) memory, which involves conscious recall of facts and events. Implicit (nondeclarative) memory, such as skills like riding a bike or swimming, typically remains unaffected because it is thought to be stored in different brain areas<sup>1</sup>. There are several types of amnesia, and they can be caused by various factors including brain injury, disease affecting the brain, certain medications, or psychological trauma.

The effects on memory can range from difficulty forming new memories (anterograde amnesia) to trouble recalling past experiences (retrograde amnesia).

Transient global amnesia (TGA) is a specific type of amnesia characterized by a sudden, temporary episode of memory loss, during which the individual cannot form new memories and may have difficulty recalling past events. These episodes are usually brief, typically lasting for several hours, after which the person's memory gradually returns, and there is no lasting damage to memory<sup>2</sup>. The cause of TGA is not entirely understood, but it's thought to be related to temporary disruption of blood flow to certain parts of the brain that are involved in memory formation and retrieval. Recent MRI data suggest that a transient perturbation of hippocampal function is the functional correlate of TGA because focal diffusion lesions can be detected in the CA1 field of the hippocampal cornu ammonis<sup>3</sup>. Nonetheless, these data are inconclusive. Notably, a diagnosis of TGA is not given when the amnesia may be related to stroke, epilepsy/seizure or neurodegenerative disease<sup>4</sup>.

Age and migraine are established risk factors to trigger TGA<sup>3</sup>. Historically, genetics has been a powerful approach to gain insights into the causal biology of poorly understood conditions<sup>5</sup>. Here, we use genetic analysis of transient global amnesia from global population biobanks to better understand memory. First, FinnGen has directly genotyped and aggregated phenotype outcomes in over 470,000 individuals from Finland, an isolated population with recent bottlenecks that offers an opportunity for studying genetic variants in complex phenotypes<sup>6</sup>. Second, UK Biobank has genotyped and aggregated medical records and phenotypes from over 500,000 individuals<sup>7,8</sup> living in the UK. Third, AllofUS has sequenced and aggregated phenotype outcomes in over 240,000 individuals from the United States<sup>9</sup>.

## Results

## Exploration of phenotypes in Finland correlated with transient global amnesia in time

Public summary data from FinRegistry, a research project that utilizes the registry system in Finland to combine health data with a wide range of information from nearly the whole population of Finland, indicates that transient global amnesia is associated with transient ischemic attack (Ji = 1.62). In FinnGen we find consistent signals where transient cerebral ischemic attack is associated with a 3.3-fold increased risk of transient global amnesia (-log10(P) = 80.8). Nonetheless, only 453 out of the 3020 matched cases that exhibit transient global amnesia have had an episode of transient cerebral ischemic attack.


## Genome-wide meta-analysis identifies 9 loci associated with transient global amnesia

We undertook a meta-analysis of three transient global amnesia genome-wide association studies (GWAS) from FinnGen (number of cases = 3315, number of controls = 471,699), UK Biobank (number of cases = 692, number of controls = 413,669), and AllofUS (number of cases = 296 cases, number of controls = 124,781). We identified 9 new susceptibility loci meeting genome-wide significance as there has been no prior GWAS study conducted of TGA (see **Figure 1A**, see **Table 1**,  $P < 5 \times 10^{-8}$ ).

A quantile-quantile plot of the primary meta-statistic using single-SNP z-scores combined across all sample sets showed a marked excess of significant associations (see **Figure 1B**).

### Genetic correlation of transient global amnesia

Genetic correlation estimates are measures that describe the degree of shared genetic influences between two traits or disorders. These estimates can provide insights into whether and how strongly genetic factors contribute to the covariance between traits. Several factors can influence these estimates including pleiotropy, evolutionary history including genetic drift and selective pressures, and ascertainment bias (for example certain individuals may be excluded from the definition of a case thereby giving the appearance that the genetics of a trait has the opposite effect on the trait that was excluded). Here, we estimate the correlation of genetic effects between transient global amnesia and FinnGen phenotypes using LD score regression<sup>10</sup>. LD score regression uses genome-wide data to estimate the correlation of genetic effect parameters thereby not restricting to genome-wide significant findings. We find the genetics of nontraumatic intracranial haemorrhage and migraine to be positively correlated with the genetics of transient global amnesia (rg = 0.29, P = .0016; rg = 0.16, P = 0.0035, respectively. see Figure 2). In addition, we find the genetics of specific development disorders of scholastic skills to be inversely correlated with the genetics of transient global amnesia (rg = -0.48, P = .0006). Specific developmental disorders of scholastic skills refers to disorders in which the normal patterns of skill acquisition are disturbed from the early stages of development. It is not simply a consequence of mental retardation, and it is not due to any form of acquired brain trauma or disease<sup>11</sup>. Similarly, the genetics of senile degeneration of the brain and myositis ossificans were inversely correlated with the genetics of TGA (rg = -0.42, P = 0.005; rg = -0.33, P = .0045, respectively, see **Figure 2**).






Figure 1. a) Manhattan plot of genome-wide association meta-analysis for transient global amnesia. Summary statistics from GWAS analysis of 3,315 transient global amnesia

cases and 471,669 controls in FinnGen were combined with summary statistics from GWAS analysis of 692 TGA cases and 413,669 controls in UK Biobank, and 296 TGA cases and 124,781 controls in AllofUS. (x-axis) genomic position of genetic variant, (y-axis) -log10(P-value) of tested genetic variant. b) Q-Q plot of p-values from genetic association meta-analysis for transient global amnesia. (x-axis) -log10(expected P-value) and (y-axis) -log10(observed P-value).




Figure 2. Estimates of the correlation of genetic effects between TGA and other phenotypes across FinnGen and UK Biobank. (x-axis) rg estimate between TGA and (y-axis) phenotype. rg +/- SE is shown, LD score regression *P* value is shown in text. Phenotypes with *P* < .01 are shown.

#### Phenome-wide association of 9 TGA lead variants

Given the overall overlap of genetic effects with other conditions we asked whether the top 8 Transient global amnesia associated variants had patterns of pleiotropic effects (assessed as P < 5x10<sup>-5</sup>) or whether the effects were specific to TGA. Of the 9 loci, 5 had evidence of being associated with another condition including coronary revascularization and myocardial infarction (n = 2), hypertension (n = 2), and pulse rate and pulse pressure (n=2). Although we did find that the genetic variant proximal to FOXF2 associated with TGA also associates to stroke, the effects are in the opposite direction (see Supplementary Table 1). To our surprise, multiple of the genetic variants that are significantly associated with transient global amnesia are specific, i.e. P > 5x10<sup>-5</sup> across all conditions assessed across both UK Biobank and FinnGen. In particular, we find that the associated variant, rs72744832 (OR = 1.41), an intronic variant in LMOD1 does not associate with other diseases, but is associated with lean mass phenotypes in UK Biobank. *LMOD1* has high observed expression in tibial, coronary, and aorta artery (median TPM > 800), however quantitative trait analysis does not reveal any specific overlap that may indicate the genetic variant is involved in regulating expression of LMOD112. In addition to the cardiovascular phenotypic overlaps being the most prominent, of the 7 genes noted in table 1 as the most likely based on proximity, 4 of these (LMOD1, CRIP1, ACTN4, MYH11) have extremely strong arterial expression in GTEx, while two others (ARHGAP42 and IPMK) are more broadly expressed including substantial arterial expression.

To explore more specifically these potential genes, we used the Enrichr tool<sup>13</sup> program to probe two recently published compendia of cellular profiles: CellMarker<sup>13,14</sup> and Tabula Sapiens. The top associations are shown in **Supplementary Table 2** - of note, the most significant enrichment is with Mural cell brain expression in mouse (p = 9.2e-7, OR = 244) and among human cells in Tabula Sapiens, the three equally enriched cell types (p<.001) include vascular pericyte cells (the subset of mural cells relevant to small vessels/capillaries) (p = 6.7e-4, OR = 67)<sup>13</sup>.


Variant ID	rsids	nearest_genes	OR	META_pval	Cell type expression
1-201926536-T-C	rs72744832	LMOD1	1.41	7.19E-27	Pericyte cell
14-105488368-C-T	rs55633823	CRIP1	1.19	1.93E-11	Vascular endothelial cells in cerebellum
19-38694171-G-A	rs7251903	ACTN4	0.87	1.24E-10	Vascular endothelial cells in cerebellum
2-203331895-C-T	rs116426890	many	1.22	4.90E-10	
6-1366655-G-T	rs192238573	FOXF2	0.79	5.52E-10	Mural cell brain
16-15814272-T-G	rs12919510	MYH11	1.14	3.00E-09	Pericyte cell
11-100639014-A-T	rs10894996	ARHGAP42	0.87	4.06E-09	

#### Table 1. FinnGen and UK Biobank meta-analysis associated variants with index SNP.

Genetic variants with P value <  $5 \times 10^{-8}$  are shown. Variant ID corresponds to chromosome-position-ref-alt for hg38 build, rsids column correspond to the rsID of the index variant, nearest genes is the gene proximal to index SNP (when most associated SNPs are localized intrinsically or in a small intergenic region), beta corresponds to estimated log(odds ratio), META\_pval correspond to the meta analysis p-value when combining genetic effects estimated in FinnGen and UK Biobank, FINNGEN\_af\_alt corresponds to the allele frequency of the alternate allele in FinnGen and UKBB\_af\_alt corresponds to the allele frequency of the alternate allele in UK Biobank. For two loci, associated variants spanned long regions of LD with equivalent evidence for ~10 genes, and for one (CRIP1) the gene was nominated based on the lead variant being a missense variant. All variants displayed had a P value > .05 for heterogeneity of genetic effects, i.e. no significant evidence of heterogeneity observed.

## Protein-altering variant, p.Ala58Val, in *CRIP1* is associated with memory loss

Given established enrichment (along with improved interpretability) of protein-altering variants associated with disease  $^{15,16}$  we asked whether any of the significantly associated variants pinpointed protein-altering variants that associate with TGA. Here, we found that a missense variant, p.Ala58Val, in *CRIP1* associates with transient global amnesia (meta-analysis  $P = 2.1 \times 10^{-11}$ , see **Figure 3**) - top index SNP in the region. The genetic variant has consistent effects in UK Biobank (odds ratio = 1.28,  $P = 3.1 \times 10^{-5}$ ) and FinnGen (odds ratio = 1.17,  $P = 6.9 \times 10^{-8}$ ) highlighting the robustness of the association. *CRIP1* is found to be highly expressed in coronary, tibial, and aorta artery tissue  $^{12}$ . CRIP1 has a role in zinc absorption and functions as an intracellular zinc transport protein  $^{17,18}$ . This variant has been previously noted as the most likely causal variant (0.75 < PIP < 1) underlying genome wide associations to increased height and heel bone mineral density and decreased calcium levels in UK Biobank quantitative trait analyses  $^{19}$ .



**Figure 3.** *CRIP1* **locus associated with transient global amnesia.** On the x-axis is the location and gene diagram of the *CRIP1* locus. The scatter plot shows the associated variants, y-axis corresponds to the -log10(meta analysis *P* value). Highlighted is the missense variant, p.Ala58Val, in *CRIP1*. Location of CRIP1 p.Ala58Val mutation in protein structure UniProt P50238.

## Discussion

In this study we present the first genetic dissection of transient global amnesia, an unusual form of transient memory loss attributable to factors beyond those observed in Alzheimer's disease or secondary to stroke or seizure. Using genome wide association across three biobanks, totalling 4303 cases and more than 1 million controls, we identify nine genome wide significant associations.

Notably, the variants identified in this study overlap with previously documented associated variants to several cardiovascular phenotypes - with multiple hits to coronary revascularization, hypertension and pulse pressure among the associations with prior evidence of association. Along with a majority of implicated genes showing extremely strong expression in artery, this lends strong support to the hypothesis that TGA may have a largely vascular origin, rather than a neuronal one. The same susceptibility origin has previously been noted for migraine, one of the main established risk factors for TGA, though the associations described here are not broadly here seen in migraine.

One of the nine associations points strongly to a missense variant in CRIP1 that has previously been implicated as the likely causal variant in increased height and bone mineral density along with lower serum calcium levels. We anticipate that these results may open new opportunities towards understanding, in particular, the vascular components of memory and memory loss, providing genes and variants for deeper molecular and phenotypic exploration.

### References

- Russell, W. R. The Traumatic Amnesias. (Oxford University Press, USA, 1971).
- Ropper, A. H. Transient Global Amnesia. N. Engl. J. Med. 388, 635–640 (2023).
- 3. Bartsch, T. & Deuschl, G. Transient global amnesia: functional anatomy and clinical implications. *Lancet Neurol.* **9**, 205–214 (2010).
- 4. Nehring, S. M., Spurling, B. C. & Kumar, A. Transient Global Amnesia. in *StatPearls*[Internet] (StatPearls Publishing, 2024).
- 5. Rommens, J. M. *et al.* Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science* **245**, 1059–1065 (1989).
- 6. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* **613**, 508–518 (2023).

- 7. Allen, N. E. *et al.* Prospective study design and data analysis in UK Biobank. *Sci. Transl. Med.* **16**, eadf4428 (2024).
- 8. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

  Nature **562**, 203–209 (2018).
- Genomic data in the All of Us Research Program. Nature 627, 340–346 (2024).
- Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.
   Nat. Genet. 47, 1236–1241 (2015).
- 11. Weindrich, D., Jennen-Steinmetz, C., Laucht, M., Esser, G. & Schmidt, M. H. Epidemiology and prognosis of specific disorders of language and scholastic skills. *Eur. Child Adolesc.*Psychiatry 9, 186–194 (2000).
- 12. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**, 648–660 (2015).
- 13. Chen, E. Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* **14**, 128 (2013).
- Hu, C. et al. CellMarker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data. *Nucleic Acids Res.* 51, D870–D876 (2023).
- 15. Tanigawa, Y. *et al.* Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma. *PLoS Genet.* **16**, e1008682 (2020).
- Sun, B. B. et al. Genetic associations of protein-coding variants in human disease. Nature
   603, 95–102 (2022).
- 17. O'Dell, B. L. Cysteine-rich intestinal protein (CRIP): a new intestinal zinc transport protein.

  Nutr. Rev. **50**, 232–233 (1992).
- Zhang, L. et al. Cysteine-rich intestinal protein 1 suppresses apoptosis and chemosensitivity to 5-fluorouracil in colorectal cancer through ubiquitin-mediated Fas degradation. J. Exp. Clin. Cancer Res. 38, 120 (2019).

## **Author information**

#### **FinnGe**

n

Full Name	Affiliation	E-mail	Role 1	Role 2
Aarno Palotie	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	aarno.palotie l @helsinki.fi		Steering Committee
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	mark.daly@h l elsinki.fi		Steering Committee
Bridget Riley-Gills	Abbvie, Chicago, IL, United States	bridget.rileygi llis@abbvie.c om		Pharmaceut ical companies
Howard Jacob	Abbvie, Chicago, IL, United States	howard.jacob @abbvie.co m		Pharmaceut ical companies
Coralie Viollet	Astra Zeneca, Cambridge, United Kingdom	coralie.viollet @astrazenec a.com		Pharmaceut ical companies
Slavé Petrovski	Astra Zeneca, Cambridge, United Kingdom	slav.petrovski @astrazened a.com		Pharmaceut ical companies
Chia-Yen Chen	Biogen, Cambridge, MA, United States	chiayen.chen @biogen.co m		Pharmaceut ical companies
Sally John	Biogen, Cambridge, MA, United States	sally.john@bi ogen.com	Steering Committe e	Pharmaceut ical companies
George Okafo	Boehringer Ingelheim, Ingelheim am Rhein, Germany	george.okafo @boehringer -ingelheim.co m	Committe	

Robert Plenge	Bristol Myers Squibb, New York, NY, United States	robert.plenge @bms.com	Steering Committe e	Pharmaceut ical companies
Joseph Maranville	Bristol Myers Squibb, New York, NY, United States	joseph.marar ville@bms.co m	_	Pharmaceut ical companies
Mark McCarthy	Genentech, San Francisco, CA, United States	mccarthy.mar k@gene.com	_	Pharmaceut ical companies
Rion Pendergra ss	Genentech, San Francisco, CA, United States	penders2@g ene.com	Steering Committe e	Pharmaceut ical companies
Jonathan Davitte	GlaxoSmithKline, Collegeville, PA, United States	jonathan.m.d avitte@gsk.c om		Pharmaceut ical companies
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.x.auro@ gsk.com	Steering Committe e	Pharmaceut ical companies
Simonne Longerich	Merck, Kenilworth, NJ, United States	simonne.long erich@merck .com		Pharmaceut ical companies
Anders Mälarstig	Pfizer, New York, NY, United States	anders.malar stig@pfizer.c om		Pharmaceut ical companies
Anna Vlahiotis	Pfizer, New York, NY, United States	anna.vlahioti s@pfizer.com	_	Pharmaceut ical companies
Katherine Klinger	Translational Sciences, Sanofi R&D, Framingham, MA, USA	katherine.klin ger@sanofi.c om		Pharmaceut ical companies
Clement Chatelain	Translational Sciences, Sanofi R&D, Framingham, MA, USA	clement.chat elain@sanofi com	_	Pharmaceut ical companies
Jorg Blankenste in	Translational Sciences, Sanofi R&D, Framingham, e MA, USA	jorg.blankens tein@sanofi.c om	_	Pharmaceut ical companies
Karol Estrada	Maze Therapeutics, San Francisco, CA, United States	kestrada@m azetx.com	Steering Committe e	
Robert Graham	Maze Therapeutics, San Francisco, CA, United States	rgraham@m azetx.com	Steering Committe e	

Dawn Waterwort h	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@it s.jnj.com	Steering Committe e	
Chris O'Donnell	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	chris.odonnel I@novartis.co m		
Nicole Renaud	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	nicole.renaud @novartis.co m	_	
Tomi P. Mäkelä	HiLIFE, University of Helsinki, Finland, Finland	tomi.makela @helsinki.fi	•	University of Helsinki & Biobanks
Jaakko Kaprio	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	jaakko.kaprio @helsinki.fi	_	University of Helsinki & Biobanks
Minna Ruddock	Arctic biobank / University of Oulu	minna.ruddoo k@oulu.fi		University of Helsinki & Biobanks
Petri Virolainen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland	petri.virolaine n@tyks.fi	_	University of Helsinki & Biobanks
Antti Hakanen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland	antti.hakanen @tyks.fi	_	University of Helsinki & Biobanks
Terhi Kilpi	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	terhi.kilpi@thl .fi	_	University of Helsinki & Biobanks
Markus Perola	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	markus.perol a@thl.fi		University of Helsinki & Biobanks
Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland	jukka.partane n@veripalvel u.fi		University of Helsinki & Biobanks
Taneli Raivio	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	taneli.raivio@ hus.fi	_	University of Helsinki & Biobanks
Jani Tikkanen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	jani.tikkanen @pohde.fi		University of Helsinki & Biobanks
Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	raisa.serpi@ oulu.fi	Steering Committe e	University of Helsinki & Biobanks

-	4
-	1

Kati Kristiansso n	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland	kati.kristianss on@pirha.fi		_
Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland	veli-matti.kos ma@uef.fi		University of Helsinki & Biobanks
Jari Laukkanen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland	jari.laukkane n@hyvaks.fi	_	_
Marco Hautalahti	FINBB - Finnish biobank cooperative	marco.hautal ahti@finbb.fi	_	University of Helsinki & Biobanks
Outi Tuovila	Business Finland, Helsinki, Finland	outi.tuovila@ businessfinla nd.fi	_	
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@ abbvie.com	Scientific Committe e	
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygi llis@abbvie.c om		Pharmaceut ical companies
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov @abbvie.co m		Pharmaceut ical companies
Ioanna Tachmazid ou	Astra Zeneca, Cambridge, United Kingdom	ioanna.tachm azidou@astr azeneca.com	Committe	Pharmaceut ical companies
Chia-Yen Chen	Biogen, Cambridge, MA, United States	chiayen.chen @biogen.co m		Pharmaceut ical companies
Zhihao Ding	Boehringer Ingelheim, Ingelheim am Rhein, Germany	zhihao.ding @boehringer -ingelheim.co m	Committe	Pharmaceut ical companies
Marc Jung	Boehringer Ingelheim, Ingelheim am Rhein, Germany	marc_oliver.j ung@boehrin ger-ingelheim .com	Committe	
Hanati Tuoken	Boehringer Ingelheim, Ingelheim am Rhein, Germany	hanati.tuoken @boehringer -ingelheim.co m	Committe	

Shameek Biswas	Bristol Myers Squibb, New York, NY, United States	Shameek.Bis was@bms.co m		
Rion Pendergra ss	Genentech, San Francisco, CA, United States	penders2@g ene.com	Scientific Committe e	
Jonathan Davitte	GlaxoSmithKline, Collegeville, PA, United States	jonathan.m.d avitte@gsk.c om		
Neha Raghavan	Merck, Kenilworth, NJ, United States	neha.raghav an@merck.c om		
Adriana Huertas-Va zquez	Merck, Kenilworth, NJ, United States	adriana.huert as.vazquez@ merck.com		
Jae-Hoon Sul	Merck, Kenilworth, NJ, United States	jae.hoon.sul @merck.com		
Anders Mälarstig	Pfizer, New York, NY, United States	anders.malar stig@pfizer.c om		
Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfiz er.com	Scientific Committe e	
Åsa Hedman	Pfizer, New York, NY, United States	asa.hedman @pfizer.com		
Katherine Klinger	Translational Sciences, Sanofi R&D, Framingham, MA, USA	katherine.klin ger@sanofi.c om	Committe	Pharmaceut ical companies
Robert Graham	Maze Therapeutics, San Francisco, CA, United States	rgraham@m azetx.com	Scientific Committe e	
Dawn Waterwort h	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@it s.jnj.com	Scientific Committe e	
Nicole Renaud	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	nicole.renaud @novartis.co m		
Ma´en Obeidat	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	maen.obeidat @novartis.co m		

Jonathan Chung	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	jonathan.chu ng@novartis. com		
Jonas Zierer	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	jonas.zierer @novartis.co m		Pharmaceut ical companies
Mari Niemi	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	mari.niemi@ novartis.com		
Samuli Ripatti	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	samuli.ripatti @helsinki.fi		University of Helsinki & Biobanks
Johanna Schleutker	Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland	johanna.schl eutker@utu.fi		•
Markus Perola	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	markus.perol a@thl.fi		University of Helsinki & Biobanks
Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland	mikko.arvas @veripalvelu. fi		_
Olli Carpér	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	olli.carpen@ helsinki.fi		University of Helsinki & Biobanks
Reetta Hinttala	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	reetta.hinttala @oulu.fi		University of Helsinki & Biobanks
Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	johannes.kett unen@oulu.fi	Committe	_
Arto Mannerma a	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland	arto.manner maa@uef.fi		University of Helsinki & Biobanks
Katriina Aalto-Setä ä	Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland	katriina.aalto- setala@tuni.fi		_
Mika Kähönen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland	mika.kahone n@uta.fi		University of Helsinki & Biobanks
Jari Laukkaner	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland	jari.laukkane n@hyvaks.fi		-

Johanna Mäkelä	FINBB - Finnish biobank cooperative	johanna.mak ela@finbb.fi		University of Helsinki & Biobanks
Reetta	Northern Savo Hospital District, Kuopio, Finland	reetta.kalviai	Clinical	Neurology
Kälviäinen		nen@kuh.fi	Groups	Group
Valtteri	Northern Savo Hospital District, Kuopio, Finland	valtteri.julkun	Clinical	Neurology
Julkunen		en@kuh.fi	Groups	Group
Hilkka	Northern Savo Hospital District, Kuopio, Finland	hilkka.soinine	Clinical	Neurology
Soininen		n@uef.fi	Groups	Group
Anne	Northern Ostrobothnia Hospital District, Oulu, Finland	anne.remes	Clinical	Neurology
Remes		@oulu.fi	Groups	Group
Mikko	University of Eastern Finland, Kuopio, Finland	mikko.hiltune	Clinical	Neurology
Hiltunen		n@uef.fi	Groups	Group
Jukka	Pirkanmaa Hospital District, Tampere, Finland	jukka.peltola	Clinical	Neurology
Peltola		@pshp.fi	Groups	Group
Minna	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	minna.raivio	Clinical	Neurology
Raivio		@geri.fi	Groups	Group
Pentti	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pentti.tienari	Clinical	Neurology
Tienari		@hus.fi	Groups	Group
Juha	Hospital District of Southwest Finland, Turku, Finland	juha.rinne@t	Clinical	Neurology
Rinne		yks.fi	Groups	Group
Roosa	Hospital District of Southwest Finland, Turku, Finland	roosa.kallion	Clinical	Neurology
Kallionpää		paa@tyks.fi	Groups	Group
Juulia Partanen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland	juulia.partane n@helsinki.fi		Neurology Group
Adam Ziemann	Abbvie, Chicago, IL, United States	adam.zieman n@abbvie.co m		Neurology Group
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui @abbvie.co m	Clinical Groups	Neurology Group
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtone n@abbvie.co m		Neurology Group
Susan Eaton	Biogen, Cambridge, MA, United States	susan.eaton @biogen.co m	Clinical Groups	Neurology Group
Heiko	Biogen, Cambridge, MA, United States	heiko.runz@	Clinical	Neurology
Runz		biogen.com	Groups	Group
Sanni	Biogen, Cambridge, MA, United States	sanni.lahden	Clinical	Neurology

Lahdenper ä		pera@bioger .com	Groups	Group
Shameek Biswas	Bristol Myers Squibb, New York, NY, United States	shameek.bis was@bms.co m		Neurology Group
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@g ene.com	Clinical Groups	Neurology Group
Edmond Teng	Genentech, San Francisco, CA, United States	teng.edmond @gene.com		Neurology Group
Rion Pendergra ss	Genentech, San Francisco, CA, United States	penders2@g ene.com	Clinical Groups	Neurology Group
Fanli Xu	GlaxoSmithKline, Brentford, United Kingdom	chun-fang.2.> u@gsk.com		Neurology Group
David Pulford	GlaxoSmithKline, Stevenage, United Kingdom	david.x.pulfor d@gsk.com		Neurology Group
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro @gsk.com	Clinical Groups	Neurology Group
Laura Addis	GlaxoSmithKline, Brentford, United Kingdom	laura.x.addis @gsk.com	Clinical Groups	Neurology Group
John Eicher	GlaxoSmithKline, Brentford, United Kingdom	john.d.eicher @gsk.com	Clinical Groups	Neurology Group
Qingqin S Li	Janssen Research & Development, LLC, Titusville, NJ 08560, United States	J QLi2@its.jnj. com	Clinical Groups	Neurology Group
Karen He	Janssen Research & Development, LLC, Spring House, PA, United States	khe2@its.jnj. com	Clinical Groups	Neurology Group
Ekaterina Khramtsov a	Janssen Research & Development, LLC, Spring House, PA, United States	ekhramts@it s.jnj.com	Clinical Groups	Neurology Group
Neha Raghavan	Merck, Kenilworth, NJ, United States	neha.raghav an@merck.c om		Neurology Group
Martti Färkkilä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	martti.farkkila @hus.fi	Clinical Groups	Gastroenter ology Group
Jukka Koskela	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	jukka.koskela @helsinki.fi	Clinical Groups	Gastroenter ology Group
Sampsa Pikkaraine n	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	sampsa.pikk arainen@hus .fi		Gastroenter ology Group
Airi Jussila	Pirkanmaa Hospital District, Tampere, Finland	airi.jussila@p	Clinical	Gastroenter

Kalpala		@pfizer.com	Groups	ology Group
Melissa Miller	Pfizer, New York, NY, United States	melissa.r.mill er@pfizer.co m		Gastroenter ology Group
Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfiz er.com	Clinical Groups	Gastroenter ology Group
Kari Eklund	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	kari.eklund@ hus.fi	Clinical Groups	Rheumatolo gy Group
Antti Palomäki	Hospital District of Southwest Finland, Turku, Finland	ajpalo@utu.fi	Clinical Groups	Rheumatolo gy Group
Pia Isomäki	Pirkanmaa Hospital District, Tampere, Finland	pia.isomaki@ pshp.fi	Clinical Groups	Rheumatolo gy Group
Laura Pirilä	Hospital District of Southwest Finland, Turku, Finland	laura.pirila@t imnet.fi,laura pirila@tyks.fi		Rheumatolo gy Group
Oili Kaipiainen Seppänen		oili.kaipiainer -seppanen@ kuh.fi		Rheumatolo gy Group
Johanna Huhtakang as	Northern Ostrobothnia Hospital District, Oulu, Finland	johanna.huht akangas@ku h.fi		Rheumatolo gy Group
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@h elsinki.fi	Clinical Groups	Rheumatolo gy Group
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@ abbvie.com	Clinical Groups	Rheumatolo gy Group
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov @abbvie.co m	Clinical Groups	Rheumatolo gy Group
Apinya Lertratana kul	Abbvie, Chicago, IL, United States	apinya.lertrat anakul@abb vie.com		Rheumatolo gy Group
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui @abbvie.co m		Rheumatolo gy Group
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtone n@abbvie.co m		Rheumatolo gy Group
Coralie Viollet	AstraZeneca, Cambridge, United Kingdom	coralie.viollet @astrazened a.com		Rheumatolo gy Group
Marla	Bristol Myers Squibb, New York, NY, United States	mhochfeld@	Clinical	Rheumatolo

Hochfeld		celgene.com	Groups	gy Group
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@g ene.com	Clinical Groups	Rheumatolo gy Group
Rion Pendergra ss	Genentech, San Francisco, CA, United States	penders2@g ene.com	Clinical Groups	Rheumatolo gy Group
Jorge Esparza Gordillo	GlaxoSmithKline, Brentford, United Kingdom	jorge.x.espar za-gordillo@ gsk.com		Rheumatolo gy Group
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro @gsk.com	Clinical Groups	Rheumatolo gy Group
Dawn Waterwort h	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@it s.jnj.com	Clinical Groups	Rheumatolo gy Group
Fabiana Farias	Merck, Kenilworth, NJ, United States	fabiana.farias @merck.com		Rheumatolo gy Group
Kirsi Kalpala	Pfizer, New York, NY, United States	kirsi.kalpala @pfizer.com	Clinical Groups	Rheumatolo gy Group
Nan Bing	Pfizer, New York, NY, United States	nan.bing@pfi zer.com	Clinical Groups	Rheumatolo gy Group
Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfiz er.com	Clinical Groups	Rheumatolo gy Group
Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland	tarja.laitinen @pshp.fi	Clinical Groups	Pulmonolog y Group
Margit Pelkonen	Northern Savo Hospital District, Kuopio, Finland	margit.pelkon en@kuh.fi	Clinical Groups	Pulmonolog y Group
Paula Kauppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	paula.kauppi @hus.fi	Clinical Groups	Pulmonolog y Group
Hannu Kankaanra nta	University of Gothenburg, Gothenburg, Sweden/ Seinäjoki Central Hospital, Seinäjoki, Finland/ Tampere University, Tampere, Finland	hannu.kanka anranta@tun .fi		Pulmonolog y Group
Terttu Harju	Northern Ostrobothnia Hospital District, Oulu, Finland	terttu.harju@ oulu.fi	Clinical Groups	Pulmonolog y Group
Riitta Lahesmaa	Hospital District of Southwest Finland, Turku, Finland	rilahes@utu.f i	Clinical Groups	Pulmonolog y Group
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui @abbvie.co m	Clinical Groups	Pulmonolog y Group
Coralie Viollet	AstraZeneca, Cambridge, United Kingdom	coralie.viollet @astrazened		Pulmonolog y Group

		a.com		
Susan Eaton	Biogen, Cambridge, MA, United States	susan.eaton @biogen.co m	Clinical Groups	Pulmonolog y Group
Hubert Chen	Genentech, San Francisco, CA, United States	chenh37@ge ne.com	Clinical Groups	Pulmonolog y Group
Rion Pendergra ss	Genentech, San Francisco, CA, United States	penders2@g ene.com	Clinical Groups	Pulmonolog y Group
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@g ene.com	Clinical Groups	Pulmonolog y Group
Joanna Betts	GlaxoSmithKline, Brentford, United Kingdom	joanna.c.bett s@gsk.com	Clinical Groups	Pulmonolog y Group
Kirsi Auro	GlaxoSmithKline, Espoo, Finland		Clinical Groups	Pulmonolog y Group
Rajashree Mishra	GlaxoSmithKline, Brentford, United Kingdom	rajashree.x.m ishra@gsk.co m		Pulmonolog y Group
Majd Mouded	Novartis, Basel, Switzerland	majd.mouded @novartis.co @		Pulmonolog y Group
Debby Ngo	o Novartis, Basel, Switzerland	debby.ngo@ novartis.com		Pulmonolog y Group
Teemu Niiranen	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	teemu.niirane n@thl.fi	Clinical Groups	Cardiometa bolic Diseases Group
Felix Vaura	a Finnish Institute for Health and Welfare (THL), Helsinki, Finland	fechva@utu.f( i	Clinical Groups	Cardiometa bolic Diseases Group
Veikko Salomaa	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	veikko.salom ( aa@thl.fi	Clinical Groups	Cardiometa bolic Diseases Group
Kaj Metsärinne	Hospital District of Southwest Finland, Turku, Finland	•	Clinical Groups	Cardiometa bolic Diseases Group
Jenni Aittokallio	Hospital District of Southwest Finland, Turku, Finland		Clinical Groups	Cardiometa bolic Diseases

				Group
Mika Kähönen	Pirkanmaa Hospital District, Tampere, Finland	mika.kahone n@uta.fi	Clinical Groups	Cardiometa bolic Diseases Group
Jussi Hernesnie mi	Pirkanmaa Hospital District, Tampere, Finland	jussi.hernesn iemi@tuni.fi	Clinical Groups	Cardiometa bolic Diseases Group
Daniel Gordin	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	daniel.gordin @hus.fi	Clinical Groups	Cardiometa bolic Diseases Group
Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	juha.sinisalo @hus.fi	Clinical Groups	Cardiometa bolic Diseases Group
Marja-Riitt a Taskinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	marja-riitta.ta skinen@helsi nki.fi		Cardiometa bolic Diseases Group
Tiinamaija Tuomi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tiinamaija.tuo mi@hus.fi	Clinical Groups	Cardiometa bolic Diseases Group
Timo Hiltunen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	timo.hiltunen @hus.fi	Clinical Groups	Cardiometa bolic Diseases Group
Jari Laukkanen	Central Finland Health Care District, Jyväskylä, Finland	jari.laukkane n@hyvaks.fi		Cardiometa bolic Diseases Group
Amanda Elliott	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston, MA, USA	aelliott@broa dinstitute.org		Cardiometa bolic Diseases Group
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@ helsinki.fi	Clinical Groups	Cardiometa bolic Diseases Group
Sanni Ruotsalain	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	sanni.ruotsal ainen@helsin		Cardiometa bolic

en		ki.fi		Diseases Group
Dirk Paul	Astra Zeneca, Cambridge, United Kingdom	dirk.paul@as trazeneca.co m		Cardiometa bolic Diseases Group
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@g ene.com	Clinical Groups	Cardiometa bolic Diseases Group
Rion Pendergra ss	Genentech, San Francisco, CA, United States	penders2@g ene.com	Clinical Groups	Cardiometa bolic Diseases Group
Audrey Chu	GlaxoSmithKline, Brentford, United Kingdom	audrey.y.chu @gsk.com	Clinical Groups	Cardiometa bolic Diseases Group
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro @gsk.com	Clinical Groups	Cardiometa bolic Diseases Group
Dermot Reilly	Janssen Research & Development, LLC, Boston, MA, United States	dreill11@its.j nj.com	Clinical Groups	Cardiometa bolic Diseases Group
Mike Mendelsor	Novartis, Boston, MA, United States	mike.mendel son@novarti s.com		Cardiometa bolic Diseases Group
Jaakko Parkkinen	Pfizer, New York, NY, United States	jaakko.parkki nen@pfizer.c om		Cardiometa bolic Diseases Group
Melissa Miller	Pfizer, New York, NY, United States	melissa.r.mill er@pfizer.co m		Cardiometa bolic Diseases Group
Tuomo Meretoja	Department of Breast Surgery, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland	tuomo.meret oja@hus.fi	Clinical Groups	Oncology Group
Heikki Joensuu	Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of	heikki.joensu u@hus.fi	Clinical Groups	Oncology Group

#### Helsinki, Helsinki, Finland

	, ,			
Olli Carpér	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	olli.carpen@ helsinki.fi	Clinical Groups	Oncology Group
Johanna Mattson	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	johanna.matt son@hus.fi	Clinical Groups	Oncology Group
Eveliina Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	eveliina.e.sal minen@hus.f i		Oncology Group
Annika Auranen	Pirkanmaa Hospital District , Tampere, Finland	anaura@utu.t i	Clinical Groups	Oncology Group
Peeter Karihtala	Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland	peeter.karihta la@hus.fi	Clinical Groups	Oncology Group
Päivi Auvinen	Northern Savo Hospital District, Kuopio, Finland	paivi.auvinen @kuh.fi	Clinical Groups	Oncology Group
Klaus Elenius	Hospital District of Southwest Finland, Turku, Finland	klaus.elenius @utu.fi	Clinical Groups	Oncology Group
Johanna Schleutker	Hospital District of Southwest Finland, Turku, Finland	johanna.schl eutker@utu.fi		Oncology Group
Esa Pitkänen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	esa.pitkanen @helsinki.fi	Clinical Groups	Oncology Group
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@h elsinki.fi	Clinical Groups	Oncology Group
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	mark.daly@h elsinki.fi	Clinical Groups	Oncology Group
Relja Popovic	Abbvie, Chicago, IL, United States	relja.popovic @abbvie.co m	Clinical Groups	Oncology Group
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@ abbvie.com	Clinical Groups	Oncology Group
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygi Ilis@abbvie.c om		Oncology Group
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtone n@abbvie.co m		Oncology Group
Margarete Fabre	AstraZeneca, Cambridge, United Kingdom	margarete.fa bre@astraze neca.com		Oncology Group

Jennifer Schutzmar	Genentech, San Francisco, CA, United States	schutzman.je nnifer@gene. com		Oncology Group
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@g ene.com	Clinical Groups	Oncology Group
Rion Pendergra ss	Genentech, San Francisco, CA, United States	penders2@g ene.com	Clinical Groups	Oncology Group
Diptee Kulkarni	GlaxoSmithKline, Brentford, United Kingdom	diptee.a.kulk arni@gsk.co m		Oncology Group
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro @gsk.com	Clinical Groups	Oncology Group
Alessandro Porello	Janssen Research & Development, LLC, Spring House, PA, United States	APorrell@IT S.JNJ.com	Clinical Groups	Oncology Group
Andrey Loboda	Merck, Kenilworth, NJ, United States	andrey_lobod a@merck.co m		Oncology Group
Heli Lehtonen	Pfizer, New York, NY, United States	heli.lehtonen @pfizer.com		Oncology Group
Stefan McDonoug h	Pfizer, New York, NY, United States	stefan.McDo nough@pfize r.com		Oncology Group
Sauli Vuoti	Janssen-Cilag Oy, Espoo, Finland	svuoti@its.jnj .com	Clinical Groups	Oncology Group
Kai Kaarnirant a	Northern Savo Hospital District, Kuopio, Finland; Department of Molecular Genetics, University of Lodz, Lodz, Poland	kai.kaarnirant a@uef.fi	Clinical Groups	Opthalmolo gy Group
Joni A Turunen	Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland	joni.turunen @helsinki.fi		Opthalmolo gy Group
Terhi Ollila	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	terhi.ollila@h us.fi	Clinical Groups	Opthalmolo gy Group
Hannu Uusitalo	Pirkanmaa Hospital District, Tampere, Finland	hannu.uusital o@tuni.fi	Clinical Groups	Opthalmolo gy Group
Juha Karjalainer	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	juha.karjalain en@helsinki.f i		Opthalmolo gy Group
Esa Pitkänen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	esa.pitkanen @helsinki.fi	Clinical Groups	Opthalmolo gy Group
Mengzhen	Abbvie, Chicago, IL, United States	mengzhen.liu	Clinical	Opthalmolo

Liu		@abbvie.co m	Groups	gy Group
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@ biogen.com	Clinical Groups	Opthalmolo gy Group
Stephanie Loomis	Biogen, Cambridge, MA, United States	stephanie.loc mis@biogen. com		Opthalmolo gy Group
Erich Strauss	Genentech, San Francisco, CA, United States	strauss.erich @gene.com		Opthalmolo gy Group
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@g ene.com	Clinical Groups	Opthalmolo gy Group
Hao Chen	Genentech, San Francisco, CA, United States	haoc@gene. com	Clinical Groups	Opthalmolo gy Group
Rion Pendergra ss	Genentech, San Francisco, CA, United States	penders2@g ene.com	Clinical Groups	Opthalmolo gy Group
Kaisa Tasanen	Northern Ostrobothnia Hospital District, Oulu, Finland	kaisa.tasane n-maatta@ou lu.fi		Dermatolog y Group
Laura Huilaja	Northern Ostrobothnia Hospital District, Oulu, Finland	laura.huilaja @oulu.fi	Clinical Groups	Dermatolog y Group
Katariina Hannula-J ouppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	katariina.han nula-jouppi@ hus.fi		Dermatolog y Group
Teea Salm	i Pirkanmaa Hospital District, Tampere, Finland	teea.salmi@ pshp.fi	Clinical Groups	Dermatolog y Group
Sirkku Peltonen	Hospital District of Southwest Finland, Turku, Finland	sipelto@utu.f	i Clinical Groups	Dermatolog y Group
Leena Koulu	Hospital District of Southwest Finland, Turku, Finland	leena.koulu @tyks.fi	Clinical Groups	Dermatolog y Group
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui @abbvie.co m	Clinical Groups	Dermatolog y Group
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov @abbvie.co m		Dermatolog y Group
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtone n@abbvie.co m		Dermatolog y Group
David Choy	Genentech, San Francisco, CA, United States	choy.david@ gene.com	Clinical Groups	Dermatolog y Group

Rion Pendergra ss	Genentech, San Francisco, CA, United States	penders2@g ene.com	Clinical Groups	Dermatolog y Group
Dawn Waterwort h	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@it s.jnj.com	Clinical Groups	Dermatolog y Group
Kirsi Kalpala	Pfizer, New York, NY, United States	kirsi.kalpala @pfizer.com	Clinical Groups	Dermatolog y Group
Ying Wu	Pfizer, New York, NY, United States	ying.wu3@pf zer.com	i Clinical Groups	Dermatolog y Group
Pirkko Pussinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pirkko.pussin en@helsinki.t i		Odontology Group
Aino Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	aino.m.salmi nen@helsink .fi		Odontology Group
Tuula Salo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuula.salo@h elsinki.fi	Clinical Groups	Odontology Group
David Rice	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	david.rice@h elsinki.fi	Clinical Groups	Odontology Group
Pekka Nieminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pekka.niemin en@helsinki.t i		Odontology Group
Ulla Palotie	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	ulla.palotie@ helsinki.fi	Clinical Groups	Odontology Group
Maria Siponen	Northern Savo Hospital District, Kuopio, Finland	maria.sipone n@uef.fi	Clinical Groups	Odontology Group
Liisa Suominen	Northern Savo Hospital District, Kuopio, Finland	liisa.suomine n@uef.fi	Clinical Groups	Odontology Group
Päivi Mäntylä	Northern Savo Hospital District, Kuopio, Finland	paivi.mantyla @uef.fi	Clinical Groups	Odontology Group
Ulvi Gursoy	Hospital District of Southwest Finland, Turku, Finland	ulvi.gursoy@ utu.fi	Clinical Groups	Odontology Group
Vuokko Anttonen	Northern Ostrobothnia Hospital District, Oulu, Finland	vuokko.antto nen@oulu.fi		Odontology Group
Kirsi Sipilä	Research Unit of Oral Health Sciences Faculty of Medicine, University of Oulu, Oulu, Finland; Medical Research Center, Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland	kirsi.sipila@o ulu.fi	Clinical Groups	Odontology Group
Rion Pendergra	Genentech, San Francisco, CA, United States	pendergrass. sarah@gene		Odontology Group

SS		com	
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hannele.laivu Clinical ori@helsinki.f Groups i	Women's Health and Reproductio n Group
Venla Kurra	Pirkanmaa Hospital District, Tampere, Finland	venla.kurra@ Clinical tuni.fi Groups	Women's Health and Reproductio n Group
Laura Kotaniemi- Talonen	Pirkanmaa Hospital District, Tampere, Finland	laura.kotanie Clinical mi-talonen@t Groups uni.fi	Women's Health and Reproductio n Group
Oskari Heikinheim o	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	oskari.heikin Clinical heimo@helsi Groups nki.fi	Women's Health and Reproductio n Group
Ilkka Kalliala	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	ilkka.kalliala Clinical @hus.fi Groups	Women's Health and Reproductio n Group
Lauri Aaltonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	lauri.aaltonen Clinical @helsinki.fi Groups	Women's Health and Reproductio n Group
Varpu Jokimaa	Hospital District of Southwest Finland, Turku, Finland	varpu.jokima Clinical a@utu.fi Groups	Women's Health and Reproductio n Group
Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland	Johannes.Ke Clinical ttunen@oulu. Groups fi	Women's Health and Reproductio n Group
Marja Vääräsmä ki	Northern Ostrobothnia Hospital District, Oulu, Finland	marja.vaaras Clinical maki@oulu.fi Groups	Women's Health and Reproductio n Group
Outi Uimar	i Northern Ostrobothnia Hospital District, Oulu, Finland	outi.uimari@ Clinical oulu.fi Groups	Women's Health and Reproductio n Group
Laure Morin-Pap	Northern Ostrobothnia Hospital District, Oulu, Finland	Imp@cc.oulu. Clinical fi Groups	Women's Health and

unen				Reproductio n Group
Maarit Niinimäki	Northern Ostrobothnia Hospital District, Oulu, Finland	maarit.niinim aki@oulu.fi	Clinical Groups	Women's Health and Reproductio n Group
Terhi Piltonen	Northern Ostrobothnia Hospital District, Oulu, Finland	terhi.piltonen @oulu.fi	Clinical Groups	Women's Health and Reproductio n Group
Katja Kivinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	katja.kivinen @helsinki.fi	Clinical Groups	Women's Health and Reproductio n Group
Elisabeth Widen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elisabeth.wid en@helsinki.f i		Women's Health and Reproductio n Group
Taru Tukiainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	taru.tukiainen @helsinki.fi	Clinical Groups	Women's Health and Reproductio n Group
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@ helsinki.fi	Clinical Groups	Women's Health and Reproductio n Group
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	mark.daly@h elsinki.fi	Clinical Groups	Women's Health and Reproductio n Group
Niko Välimäki	University of Helsinki, Helsinki, Finland	niko.valimaki @helsinki.fi	Clinical Groups	Women's Health and Reproductio n Group
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland	eija.k.laakkon en@jyu.fi	Clinical Groups	Women's Health and Reproductio n Group
Jaakko Tyrmi	University of Oulu, Oulu, Finland / University of Tampere, Tampere, Finland	jaakko.tyrmi @oulu.fi	Clinical Groups	Women's Health and Reproductio n Group
Heidi	University of Oulu, Oulu, Finland	heidi.silven@	Clinical	Women's

Silven		student.oulu.i	f Groups	Health and Reproductio n Group
Eeva Sliz	University of Oulu, Oulu, Finland	eeva.sliz@ou lu.fi	Clinical Groups	Women's Health and Reproductio n Group
Riikka Arffman	University of Oulu, Oulu, Finland	riikka.arffman @oulu.fi	Clinical Groups	Women's Health and Reproductio n Group
Susanna Savukoski	University of Oulu, Oulu, Finland	susanna.sav ukoski@oulu fi		Women's Health and Reproductio n Group
Triin Laisk	Estonian biobank, Tartu, Estonia	triin.laisk@ut ee	Clinical Groups	Women's Health and Reproductio n Group
Natalia Pujol	Estonian biobank, Tartu, Estonia	natalia.pujolg ualdo@oulu.f i		Women's Health and Reproductio n Group
Mengzhen Liu	Abbvie, Chicago, IL, United States	mengzhen.liu @abbvie.co m		Women's Health and Reproductio n Group
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygi llis@abbvie.c om		Women's Health and Reproductio n Group
Rion Pendergra ss	Genentech, San Francisco, CA, United States	penders2@g ene.com	Clinical Groups	Women's Health and Reproductio n Group
Janet Kumar	GlaxoSmithKline, Collegeville, PA, United States	janet.x.kumai @gsk.com	Clinical Groups	Women's Health and Reproductio n Group
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro @gsk.com	Clinical Groups	Women's Health and Reproductio n Group

liris Hovatta	University of Helsinki, Finland	iiris.hovatta@ helsinki.fi	Clinical Groups	Depression group
Chia-Yen Chen	Biogen, Cambridge, MA, United States	chiayen.chen @biogen.co m		Depression group
Erkki Isometsä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	erkki.isomets a@hus.fi	Clinical Groups	Depression group
Hanna Ollila	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hanna.m.ollil a@helsinki.fi		Depression group
Jaana Suvisaari	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	jaana.suvisa ari@thl.fi	Clinical Groups	Depression group
Antti Mäkitie	Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland	antti.makitie @helsinki.fi	Clinical Groups	ENT (ear, nose and throath) Group
Argyro Bizaki-Vall askangas	Pirkanmaa Hospital District, Tampere, Finland	argyro.bizaki- vallaskangas @tuni.fi		ENT (ear, nose and throath) Group
Sanna Toppila-Sa mi	University of Eastern Finland and Kuopio University I Hospital, Department of Otorhinolaryngology, Kuopio, Finland and Department of Allergy, Helsinki University Hospital and University of Helsinki, Finland	sanna.salmi @helsinki.fi	Clinical Groups	ENT (ear, nose and throath) Group
Tytti Willberg	Hospital District of Southwest Finland, Turku, Finland	tytti.willberg @tyks.fi	Clinical Groups	ENT (ear, nose and throath) Group
Elmo Saarentau s	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elmo.saarent aus@helsinki .fi		ENT (ear, nose and throath) Group
Antti Aarnisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	antti.aarnisal o@hus.fi	Clinical Groups	ENT (ear, nose and throath) Group
Eveliina Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	eveliina.e.sal minen@hus.f i		ENT (ear, nose and throath) Group
Elisa Rahikkala	Northern Ostrobothnia Hospital District, Oulu, Finland	elisa.rahikkal a@ppshp.fi	Clinical Groups	ENT (ear, nose and throath) Group

Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland	johannes.kett unen@oulu.fi		ENT (ear, nose and throath) Group
Kristiina Aittomäki	Department of Medical Genetics, Helsinki University Central Hospital, Helsinki, Finland	kristiina.aitto maki@helsin ki.fi		POI (premature ovarian failure) Group
Fredrik Åberg	Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki University, Helsinki, Finland	fredrik.aberg @helsinki.fi	Clinical Groups	LiverScore Group
Mitja Kurki	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States	mkurki@broa dinstitute.org		FinnGen Analysis working group
Samuli Ripatti	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	samuli.ripatti @helsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Mark Daly	Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	mark.daly@h elsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Juha Karjalainer	n Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	juha.karjalain en@helsinki.f i		FinnGen Analysis working group
Aki Havulinna	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Finnish Institute for Health and Welfare (THL), Helsinki, Finland	aki.havulinna @helsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Juha Mehtonen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	juha.mehtone n@helsinki.fi		FinnGen Analysis working group
Priit Palta	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	priit.palta@h elsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Shabbeer Hassan	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	shabbeer.has san@helsinki .fi		FinnGen Analysis working group

Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	pietro.dellabri ottaparolo@h elsinki.fi		FinnGen Analysis working group
Wei Zhou	Broad Institute, Cambridge, MA, United States	wzhou@broa dinstitute.org		FinnGen Analysis working group
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States	mmaasha@b roadinstitute. org		FinnGen Analysis working group
Shabbeer Hassan	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	shabbeer.has san@helsinki .fi		FinnGen Analysis working group
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	susanna.lem mela@helsin ki.fi		FinnGen Analysis working group
Manuel Rivas	University of Stanford, Stanford, CA, United States	mrivas@stan ford.edu	FinnGen Analysis working group	FinnGen Analysis working group
Aarno Palotie	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	aarno.palotie @helsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Aoxing Liu	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	aoxing.liu@h elsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Arto Lehisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	arto.lehisto@ helsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Andrea Ganna	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	aganna@bro adinstitute.or g		FinnGen Analysis working group
Vincent Llorens	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	vincent.lloren s@helsinki.fi		FinnGen Analysis working group

Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hannele.laivu ori@helsinki.f i		FinnGen Analysis working group
Taru Tukiainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	taru.tukiainen @helsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@ helsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Henrike Heyne	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hheyne@bro adinstitute.or g		FinnGen Analysis working group
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@h elsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Joel Rämö	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	joel.ramo@h elsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Elmo Saarentau s	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elmo.saarent aus@helsinki .fi		FinnGen Analysis working group
Hanna Ollila	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hanna.m.ollil a@helsinki.fi		FinnGen Analysis working group
Satu Strausz	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	satu.strausz @helsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Tuula Palotie	University of Helsinki and Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuula.palotie @helsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Kimmo Palin	University of Helsinki, Helsinki, Finland	kimmo.palin @helsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group

Javier Garcia-Tab uenca	University of Tampere, Tampere, Finland	javier.graciat abuenca@tu ni.fi		FinnGen Analysis working group
Harri Siirtola	University of Tampere, Tampere, Finland	harri.siirtola @tuni.fi	FinnGen Analysis working group	FinnGen Analysis working group
Tuomo Kiiskinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	tuomo.kiiskin en@helsinki.f i		FinnGen Analysis working group
Jiwoo Lee	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States	jiwoo.lee@he Isinki.fi	FinnGen Analysis working group	FinnGen Analysis working group
Kristin Tsuo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States	kristintsuo@f as.harvard.e du		FinnGen Analysis working group
Amanda Elliott	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston, MA, USA	aelliott@broa dinstitute.org		FinnGen Analysis working group
Kati Kristiansso n	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	kati.kristianss on@thl.fi	FinnGen Analysis working group	FinnGen Analysis working group
Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland	mikko.arvas @veripalvelu. fi	FinnGen Analysis working group	_
Kati Hyvärinen	Finnish Red Cross Blood Service, Helsinki, Finland	kati.hyvarine n@veripalvel u.fi		FinnGen Analysis working group
Jarmo Ritari	Finnish Red Cross Blood Service, Helsinki, Finland	jarmo.ritari@ veripalvelu.fi		FinnGen Analysis working group
Olli Carpér	n Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	olli.carpen@ helsinki.fi	FinnGen Analysis working group	FinnGen Analysis working group

Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	johannes.kett unen@oulu.fi		FinnGen Analysis working group
Katri Pylkäs	University of Oulu, Oulu, Finland	katri.pylkas@ oulu.fi	FinnGen Analysis working group	FinnGen Analysis working group
Eeva Sliz	University of Oulu, Oulu, Finland	eeva.sliz@ou lu.fi	FinnGen Analysis working group	FinnGen Analysis working group
Minna Karjalainer	University of Oulu, Oulu, Finland	minna.k.karja lainen@oulu. fi		FinnGen Analysis working group
Tuomo Mantere	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	tuomo.mante re@oulu.fi	FinnGen Analysis working group	FinnGen Analysis working group
Eeva Kangasnie mi	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland	eeva.kangas niemi@pshp. fi		FinnGen Analysis working group
Sami Heikkinen	University of Eastern Finland, Kuopio, Finland	sami.heikkine n@uef.fi	FinnGen Analysis working group	FinnGen Analysis working group
Arto Mannerma a	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland	arto.manner maa@uef.fi	FinnGen Analysis working group	_
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland	eija.k.laakkon en@jyu.fi	FinnGen Analysis working group	FinnGen Analysis working group
Nina Pitkänen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland	Niina.Pitkane n@tyks.fi	FinnGen Analysis working group	FinnGen Analysis working group
Samuel Lessard	Translational Sciences, Sanofi R&D, Framingham, MA, USA	samuel.lessa rd@sanofi.co m		FinnGen Analysis working group

Clément Chatelain	Translational Sciences, Sanofi R&D, Framingham, MA, USA	clement.chat elain@sanofi. com		FinnGen Analysis working group
Lila Kallio	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland	Lila.Kallio@ty ks.fi		Biobank directors
Tiina Wahlfors	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	tiina.wahlfors @thl.fi		Biobank directors
Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland	jukka.partane n@veripalvel u.fi		
Eero Punkka	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	eero.punkka @hus.fi		Biobank directors
Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	raisa.serpi@ ppshp.fi	Biobank directors	Biobank directors
Sanna Siltanen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland	sanna.siltane n@pirha.fi		Biobank directors
Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland	veli-matti.kos ma@uef.fi		Biobank directors
Tiina Jokela	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland	tiina.a.jokela @jyu.fi		Biobank directors
Anu Jalanko	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	anu.jalanko @helsinki.fi	FinnGen Teams	Administrati on
Auli Toivola	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	auli.toivola@ helsinki.fi	FinnGen Teams	Administrati on
Huei-Yi Shen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	huei-yi.shen @helsinki.fi	FinnGen Teams	Administrati on
Risto Kajanne	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	risto.kajanne @helsinki.fi	FinnGen Teams	Administrati on
Rodos Rodosthen ous	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	rodos.rodost henous@hel sinki.fi		Administrati on
Mervi Aavikko	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mervi.aavikk o@helsinki.fi		Administrati on
Helen Cooper	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	helen.cooper @helsinki.fi	FinnGen Teams	Administrati on

Denise Öller	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	denise.oller @helsinki.fi	FinnGen Teams	Administrati on
Tarja Laitinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	tarja.laitinen @helsinki.fi	FinnGen Teams	Administrati on
Rasko Leinonen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; European Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, UK	rasko@ebi.a c.uk	FinnGen Teams	Administrati on
Henna Palin	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland	henna.palin @pshp.fi	FinnGen Teams	Administrati on
Malla-Mari a Linna	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	malla-maria.li nna@hus.fi	FinnGen Teams	Administrati on
Mitja Kurki	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States	mkurki@broa dinstitute.org		Analysis
Juha Karjalainer	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	juha.karjalain en@helsinki.f i		Analysis
Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	pietro.dellabri ottaparolo@h elsinki.fi		Analysis
Arto Lehisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	arto.lehisto@ helsinki.fi	FinnGen Teams	Analysis
Juha Mehtonen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	juha.mehtone n@helsinki.fi		Analysis
Wei Zhou	Broad Institute, Cambridge, MA, United States	wzhou@broa dinstitute.org		Analysis
Masahiro Kanai	Broad Institute, Cambridge, MA, United States	mkanai@bro adinstitute.or g		Analysis
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States	mmaasha@b roadinstitute. org		Analysis
Zhili Zheng	Broad Institute, Cambridge, MA, United States	zhengzhi@br oadinstitute.o rg		Analysis
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hannele.laivu ori@helsinki.t i		Clinical Endpoint Developmen

			t
Aki Havulinna	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Finnish Institute for Health and Welfare (THL), Helsinki, Finland	aki.havulinna FinnGen @helsinki.fi Teams	Clinical Endpoint Developmen t
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	susanna.lem FinnGen mela@helsin Teams ki.fi	Clinical Endpoint Developmen t
Tuomo Kiiskinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	tuomo.kiiskin FinnGen en@helsinki.f Teams i	Clinical Endpoint Developmen t
L. Elisa Lahtela	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	laura.lahtela FinnGen @helsinki.fi Teams	Clinical Endpoint Developmen t
Mari Kaunisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mari.kaunisto <b>FinnGen</b> @helsinki.fi <b>Teams</b>	Communica tion
Elina Kilpeläinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elina.kilpelain FinnGen en@helsinki.f Teams i	E-Science
Tianduanyi Wang	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	tianduanyi.w FinnGen ang@helsinki Teams .fi	E-Science
Timo P. Sipilä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	timo.p.sipila FinnGen @helsinki.fi Teams	E-Science
Oluwaseur Alexander Dada	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	alexander.da FinnGen da@helsinki.f Teams i	E-Science
Awaisa Ghazal	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	awaisa.ghaz FinnGen al@helsinki.fi Teams	E-Science
Anastasia Kytölä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	anastasia.sh FinnGen cherban@hel Teams sinki.fi	E-Science
Rigbe Weldatsadi k	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	rigbe.weldats FinnGen adik@helsink Teams i.fi	E-Science
Sanni Ruotsalain en	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	sanni.ruotsal FinnGen ainen@helsin Teams ki.fi	E-Science

Jaska Institute for Molecular Medicine Finland (FIMM), Uimonen HiLIFE, University of Helsinki, Helsinki, Finland	jaska.uimone n@helsinki.fi		E-Science
Kati Institute for Molecular Medicine Finland (FIMM), Donner HiLIFE, University of Helsinki, Helsinki, Finland	kati.donner@ helsinki.fi	FinnGen Teams	Genotyping
Anu Helsinki Biobank / Helsinki University and Hospital Loukola District of Helsinki and Uusimaa, Helsinki	anu.loukola @hus.fi	FinnGen Teams	Sample Collection Coordinatio n
Päivi Laiho THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	paivi.laiho@t	FinnGen	Sample
	hl.fi	Teams	Logistics
Tuuli THL Biobank / Finnish Institute for Health and Welfare Sistonen (THL), Helsinki, Finland	tuuli.sistonen	FinnGen	Sample
	@thl.fi	Teams	Logistics
Essi THL Biobank / Finnish Institute for Health and Welfare Kaiharju (THL), Helsinki, Finland	essi.kaiharju	FinnGen	Sample
	@thl.fi	Teams	Logistics
Markku THL Biobank / Finnish Institute for Health and Welfare Laukkanen (THL), Helsinki, Finland	markku.laukk	FinnGen	Sample
	anen@thl.fi	Teams	Logistics
Elina THL Biobank / Finnish Institute for Health and Welfare Järvensivu (THL), Helsinki, Finland	elina.jarvensi	FinnGen	Sample
	vu@thl.fi	Teams	Logistics
Sini THL Biobank / Finnish Institute for Health and Welfare Lähteenmä (THL), Helsinki, Finland ki	sini.lahteenm	FinnGen	Sample
	aki@thl.fi	Teams	Logistics
Lotta THL Biobank / Finnish Institute for Health and Welfare Männikkö (THL), Helsinki, Finland	lotta.mannikk	FinnGen	Sample
	o@thl.fi	Teams	Logistics
Regis THL Biobank / Finnish Institute for Health and Welfare Wong (THL), Helsinki, Finland	regis.wong@	FinnGen	Sample
	thl.fi	Teams	Logistics
Auli THL Biobank / Finnish Institute for Health and Welfare Toivola (THL), Helsinki, Finland	auli.toivola@	t FinnGen	Sample
	hl.fi	Teams	Logistics
Minna THL Biobank / Finnish Institute for Health and Welfare Brunfeldt (THL), Helsinki, Finland	minna.brunfe dt@thl.fi	l FinnGen Teams	Registry Data Operations
Susanna Lemmelä Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	susanna.lem mela@helsin ki.fi		Registry Data Operations
Sami THL Biobank / Finnish Institute for Health and Welfare Koskelaine (THL), Helsinki, Finland n	sami.koskela nen@thl.fi	i FinnGen Teams	Registry Data Operations
Tero THL Biobank / Finnish Institute for Health and Welfare Hiekkalinn (THL), Helsinki, Finland a	tero.hiekkalin na@helsinki. i		Registry Data Operations
Teemu THL Biobank / Finnish Institute for Health and Welfare Paajanen (THL), Helsinki, Finland	teemu.paajar	FinnGen	Registry
	en@thl.fi	Teams	Data

				Operations
Priit Palta	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	priit.palta@h elsinki.fi	FinnGen Teams	Sequencing Informatics
Shuang Luo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	shuang.luo@ helsinki.fi	FinnGen Teams	Sequencing Informatics
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@ helsinki.fi	FinnGen Teams	Trajectory
Shanmukh a Sampath Padmanab huni		sam.padman abhuni@hels nki.fi		Trajectory
Marianna Niemi	University of Tampere, Tampere, Finland	marianna.nie mi@tuni.fi	FinnGen Teams	Trajectory
Harri Siirtola	University of Tampere, Tampere, Finland	harri.siirtola @tuni.fi	FinnGen Teams	Trajectory
Javier Gracia-Tab uenca	University of Tampere, Tampere, Finland	javier.graciat abuenca@tu ni.fi		Trajectory
Mika Helminen	University of Tampere, Tampere, Finland	mika.helmine n@tuni.fi	FinnGen Teams	Trajectory
Tiina Luukkaala	University of Tampere, Tampere, Finland	tiina.luukkaal a@tuni.fi	FinnGen Teams	Trajectory
lida Vähätalo	University of Tampere, Tampere, Finland	iida.vahatalo @epshp.fi	FinnGen Teams	Trajectory
lina Laak	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	iina.laak@he sinki.fi	l FinnGen Teams	Data protection officer
Marco Hautalahti	Finnish Biobank Cooperative - FINBB	marco.hautal ahti@finbb.fi		FINBB - Finnish biobank cooperative
Johanna Mäkelä	Finnish Biobank Cooperative - FINBB	johanna.mak ela@finbb.fi		FINBB - Finnish biobank cooperative
Saija Haapa-Pa ananen	Finnish Biobank Cooperative - FINBB	saija.haapa-p aananen@fir bb.fi		FINBB - Finnish biobank cooperative
Sarah Smith	Finnish Biobank Cooperative - FINBB	sarah.smith @finbb.fi	FinnGen Teams	FINBB - Finnish